EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Aldosterone and Cardiovascular Risk Across the Lifespan

Roshan A Ananda iD, Trevor A Mori iD, Jun Yang

Metabolites · 17.08.2025 · 15 (8) · 553

DOI: 10.3390/metabo15080553 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 17.08.2025. Verfasst von Roshan A Ananda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Box Hill Hospital, Melbourne, VIC 3128, Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aldosterone excess, particularly in the context of primary aldosteronism, is associated with adverse cardiovascular outcomes. Historically considered a condition of resistant hypertension with hypokalaemia, patients with primary aldosteronism often experienced prolonged diagnostic delay with significant end-organ damage involving the renal, cardiovascular, and central nervous systems at diagnosis. Emerging research has revealed a wide spectrum of renin-independent aldosteronism, ranging from subclinical disease with normal or mildly elevated BP to overt disease marked by resistant hypertension and cardiovascular complications. Subclinical forms of primary aldosteronism have been identified across all age groups, and it is increasingly linked to early signs of adverse cardiac remodelling, even in young adults. Notably, adverse cardiac remodelling was independent of blood pressure. Furthermore, primary aldosteronism confers excess cardiovascular morbidity and mortality compared to blood-pressure-matched essential hypertension. Importantly, these risks can be mitigated through timely diagnosis and treatment with mineralocorticoid receptor antagonists. In this narrative review, we explore the cardiovascular consequences of aldosterone excess, discuss the pathophysiological mechanisms underlying cardiac remodelling, and examine the implications of renin-independent aldosteronism for cardiovascular risk across the lifespan.

Schlagwörter

Stichwörter der Autor:innen

aldosteronecardiovascular riskprimary aldosteronism

Autor:innen und Institutionen

  • Department of General Medicine, Box Hill Hospital, Melbourne, VIC 3128, Australia.
  • Medical School, Royal Perth Hospital Unit, University of Western Australia, Perth, WA 6000, Australia.
  • Endocrine Hypertension Group, Centre for Endocrinology and Reproductive Health, Hudson Institute of Medical Research, Melbourne, VIC 3168, Australia.
  • Department of Molecular and Translational Science, Monash University, Melbourne, VIC 3168, Australia.
  • Department of Medicine, Monash University, Melbourne, VIC 3168, Australia.

ORCID-Profile: Roshan A Ananda, Trevor A Mori

Zitieren

APA

Ananda, R. A., Mori, T. A., & Yang, J. (2025). Aldosterone and Cardiovascular Risk Across the Lifespan. Metabolites, 15(8), 553. https://doi.org/10.3390/metabo15080553

Vancouver

Ananda RA, Mori TA, Yang J. Aldosterone and Cardiovascular Risk Across the Lifespan. Metabolites. 2025;15(8):553. doi:10.3390/metabo15080553

BibTeX
@article{Ananda2025,
  author = {Ananda, Roshan A and Mori, Trevor A and Yang, Jun},
  title = {Aldosterone and Cardiovascular Risk Across the Lifespan},
  journal = {Metabolites},
  year = {2025},
  volume = {15},
  number = {8},
  pages = {553},
  doi = {10.3390/metabo15080553}
}
Kostenlos starten →